GlassScriptPhysician profile
Roger M Epstein
NPI 1821095183
$5,977.76
in general payments reported to CMS, 2019-2025
37 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $341 · 2021: $527 · 2022: $1,071 · 2023: $854 · 2024: $980 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766 · Education: $73.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.60 |
| Education | $73.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,452.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $786.35 | 2019-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $420.72 | 2019-2025 | |
| Cook Medical LLC | $294.24 | 2019 | |
| Boston Scientific Corporation | $271.82 | 2019-2022 | |
| Genzyme Corporation | $234.44 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.21 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $207.77 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $184.29 | 2019-2025 | |
| Celgene Corporation | $180.76 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $176.88 | 2020-2024 | Linzess |
| Medtronic, INC. | $158.44 | 2021-2025 | Pillcam |
| Intercept Pharmaceuticals, INC. | $146.14 | 2023-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $139.85 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $134.06 | 2019-2024 | Dificid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $127.21 | 2021-2024 | Injectafer |
| Covidien LP | $122.10 | 2019 | |
| Lilly USA, LLC | $72.67 | 2024-2025 | Omvoh |
| Allergan, INC. | $65.75 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $61.53 | 2019-2024 | Rebyota |
| Ardelyx, INC. | $51.82 | 2025 | Ibsrela |
| Celltrion USA INC. | $49.40 | 2024 | Zymfentra |
| Aimmune Therapeutics, INC. | $44.71 | 2024-2025 | Vowst |
| Braintree Laboratories, INC. | $42.47 | 2019-2020 | |
| Qol Medical, LLC | $40.12 | 2025 | Sucraid |
| Digestive Care, INC. | $38.37 | 2024 | Pertzye |
| Ucb, INC. | $35.14 | 2019 | |
| Madrigal Pharmaceuticals | $31.03 | 2025 | Rezdiffra |
| Shionogi INC | $24.46 | 2019 | |
| Amgen INC. | $23.46 | 2020-2022 | |
| Shire North American Group INC | $22.80 | 2019 | |
| Endo Pharmaceuticals INC. | $21.23 | 2019 | |
| Organon LLC | $21.01 | 2025 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $20.00 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.71 | 2021 | |
| Ethicon US, LLC | $15.44 | 2022 | |
| Pharmacosmos Therapeutics INC. | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.